GSK plc

GSK plc

25.45
USD
+0.22
(+0.88%)
1.57EPS
16.71P/E
96.27BMarket Cap
Feb 03Next Earn
GSK plc
OTC:GLAXF
(OTC Markets)

Recent

price

25.45

P/E

ratio

16.71

div

yld

3.50%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
GBP
6.97
6.81
6.73
6.86
5.98
6.19
7.17
7.72
7.84
8.53
6.12
6.17
7.28
7.48
7.7
8.06
8.35
Revenue per Share
0.4
1.31
1.14
1.41
0.72
2.18
0.23
0.39
0.92
1.17
1.44
1.1
3.71
1.22
0.63
1.41
1.08
Basic EPS, GAAP
1.27
1.22
0.73
1.43
0.89
0.17
1.07
1.21
1.69
1.48
1.63
1.32
1.28
1.09
0.88
1.17
1.56
Free Cash Flow per Basic Share
0.79
0.85
0.97
0.95
1
1
1.25
1
1
1
1
1
0.86
0.55
0.6
0.63
0.67
Dividend per Share
2.14
1.99
1.48
1.8
1.1
1.31
0.29
-0.02
0.95
2.86
3.63
3.74
2.59
3.29
3.35
4.08
4.68
Book Value per Share
-0.78
-0.87
-2.22
-1.67
-2
-4.29
-6.01
-5.89
-4.84
-7.54
-6.42
-6.35
-2.63
-2.03
-2.16
-1.84
-3.65
Tangible Book Value per Share
4,072
4,022
3,930
3,865
3,846
3,865
3,888
3,909
3,931
3,958
3,981
4,002
4,026
4,052
4,077
4,051
4,016
Basic Weighted Avg Shares
28,392
27,387
26,431
26,505
23,006
23,923
27,889
30,186
30,821
33,754
24,354
24,696
29,324
30,328
31,376
32,667
33,543
Sales/Revenue/Turnover
12.71
27.54
22.98
22.21
18.72
10.99
21.61
20.08
22.91
18.64
18.8
19.75
22.95
24.22
17.66
25.52
19.1
Operating Margin (%)
1,679
1,423
1,445
1,414
1,484
1,630
1,774
1,922
1,856
2,334
2,050
2,122
2,147
2,294
2,551
2,314
3,121
Depreciation Expense
1,634
5,261
4,499
5,436
2,756
8,422
912
1,532
3,623
4,645
5,749
4,385
14,956
4,928
2,575
5,716
4,351
Net Income, GAAP
41.31
29.1
29.12
15.33
4.62
20.46
45.23
38.47
15.71
15.32
1.3
2.31
12.56
12.47
15.13
15.02
10.42
Effective Tax Rate (%)
5.76
19.21
17.02
20.51
11.98
35.2
3.27
5.08
11.75
13.76
23.61
17.76
51
16.25
8.21
17.5
12.97
Profit Margin (%)
3,242
1,157
-123
1,550
1,383
3,170
-2,290
-10,662
-5,564
-4,559
-1,901
-4,996
-2,041
-2,424
-4,700
-3,881
-2,825
Working Capital
14,809
12,203
14,671
15,456
15,841
15,324
14,661
14,264
20,271
23,590
23,425
20,572
17,035
15,205
14,637
14,708
21,700
LT Debt
9,745
8,827
6,737
7,812
4,936
8,878
4,963
3,489
3,672
18,357
20,808
21,342
10,096
12,795
13,086
15,956
18,362
Total Equity
8.17
21.66
20.11
22.2
13.22
32.01
5.51
10.87
17.77
14.75
12.08
9.04
14.55
18.84
11.03
20.79
14.04
Return on Invested Capital (%)
7.24
23.06
19.93
22.98
13.47
36.79
4.69
6.08
15.05
12.13
12.28
9.46
39.2
16.75
9.01
17.97
12.03
Return on Capital (%)
17.3
62.19
65.05
84.96
48.95
179.63
29.24
- -
- -
61.17
44.24
29.59
116.6
41.16
19.06
38.05
24.93
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
5,044
4,291
2,001
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,020
4,007
4,009
Market Capitalization
82,823
75,888
72,575

Working Capital

GBP

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
17,761
17,559
17,895
Cash, Cash Equivalents & STI
3,443
3,106
2,962
Accounts Receivable, Net
7,756
7,706
8,223
Inventories
6,157
6,282
6,300
Total Current Liabilities
22,429
21,534
20,720
Payables & Accruals
- -
- -
- -
ST Debt
5,044
4,291
2,001
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.55%
0.16%
21.93%
Free Cash Flow
55.26%
-4.29%
33.15%
Net Income, GAAP
39.18%
44.9%
121.98%
Sales/Revenue/Turnover
3.97%
6.23%
4.11%
Total Cash Common Dividend
-2.67%
-6.85%
4.91%

Quarterly Revenue

GBP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,363
7,884
8,012
8,117
31,376
2025
7,516
7,986
8,547
8,618
32,667
2026
7,629
8,409
8,887
- -
- -

Quarterly Earnings Per Share

GBP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.26
0.29
-0.01
0.1
0.63
2025
0.4
0.36
0.5
0.16
1.41
2026
0.43
0.11
0.38
- -
- -

Quarterly Dividends Per Share

GBP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.16
0.15
0.15
0.6
2025
0.15
0.16
0.16
0.16
0.63
2026
0.16
0.18
0.17
- -
- -
Business
GSK plc operates as a global biopharmaceutical leader, dedicated to the research, development, and delivery of innovative medicines and vaccines across international markets. The company, which traces its origins back to 1715, refocused its strategy in July 2022 by spinning off its Consumer Healthcare division to form Haleon plc, thereby concentrating exclusively on its biopharma pipeline. Its operations are structured around key product areas: Specialty Medicines, Vaccines, and General Medicines. Within Specialty Medicines, GSK develops treatments for significant health challenges including HIV, oncology, respiratory conditions, and immuno-inflammatory diseases such as lupus. The Vaccines portfolio encompasses a broad range, preventing illnesses like shingles (Shingrix), meningitis, and respiratory syncytial virus (RSV) with its Arexvy vaccine. General Medicines typically address primary care needs, including inhalers for asthma and COPD, and various antibiotics. GSK generates revenue through the sale of these prescription products and vaccines to healthcare providers, hospitals, pharmacies, and governmental bodies worldwide. The company is strategically prioritizing investment in its innovative pipeline, anticipating at least twelve major product launches from 2025 in areas like infectious diseases, HIV, oncology, and respiratory health, reinforcing its commitment to scientific advancement. Recent corporate activities include strategic acquisitions such as Tesaro to bolster its oncology presence, and alliances with partners like CureVac for mRNA vaccine development. Headquartered in Brentford, United Kingdom, GSK aims to positively impact the health of 2.5 billion people by the end of the decade, driven by its purpose to unite science, technology, and talent to get ahead of disease. The company was formerly known as GlaxoSmithKline plc and adopted its current name, GSK plc, in May 2022.

Company News

  • Critical Survey: GSK (NYSE:GSK) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

  • GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments

  • GSK, Moderna settle patent dispute over Moderna COVID, RSV shots

  • HP taps Emma Walmsley, ex-GSK chief and Microsoft board member, as CEO

  • Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine

  • GSK: The Gas Pedal Is Still Down, But Bumps Ahead

  • GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

  • GSK plc (GSK) Q3 2026 Earnings Call Transcript

  • What GSK (GSK) Said on Its Q3 Earnings Call

  • GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales

  • GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat

  • GSK: Why I'm Still Bullish After Strong Q3 Results

  • GSK (GSK) Q3 Earnings and Revenues Beat Estimates

  • GSK Sales Get Boost From Specialty Medicines

  • GSK beats third-quarter profit estimates, keeps annual targets

  • GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

  • GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update

  • GSK to nearly double cancer drugs in trials, WSJ reports

  • GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

  • Can Specialty Meds Offset GSK's $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28?